US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Cartesian Therapeutics

11.83

-0.2200-1.83%

Post-market: 11.830.00000.00%16:05 EDT

Volume:45.58K

Turnover:537.96K

Market Cap:306.48M

PE:-2.64

High:12.05

Open:11.87

Low:11.51

Close:12.05

Loading ...

Overview Company News Filings

Cartesian Therapeutics management to meet with BTIG

Major Investment Alert: Director Buys Big in Cartesian Therapeutics!

Buy Rating Affirmed for Cartesian Therapeutics Due to Promising Phase 2b Trial Results and Strong Safety Profile

Cartesian Therapeutics Price Target Maintained With a $40.00/Share by HC Wainwright & Co.

Mizuho Securities Sticks to Its Buy Rating for Cartesian Therapeutics (RNAC)

Cartesian Therapeutics Shares Rise on Positive Phase 2b Trial Results

BRIEF-Cartesian Therapeutics’ Descartes-08 Observed To Provide Deep And Sustained Benefits Through Month 12 After A Single Course Of Therapy In Phase 2B Myasthenia Gravis Trial

Cartesian Therapeutics’ Descartes-08 Observed to Provide Deep and Sustained Benefits Through Month 12 After a Single Course of Therapy in Phase 2b Myasthenia Gravis Trial

Cartesian Therapeutics announces employment inducement grants

Cartesian Therapeutics Announces New Employment Inducement Grants

Oppenheimer Reaffirms Their Hold Rating on Cartesian Therapeutics (RNAC)

Buy Rating for Cartesian Therapeutics: Promising Advancements in Biopharmaceuticals and Strategic Clinical Progress

Amgen data ‘muddies’ outlook for Cartesian, says Oppenheimer

Cartesian Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag

Simply Wall St.

Cartesian Therapeutics Faces Financial Risk from Goodwill and Intangible Asset Impairments Post-Merger

Cartesian Therapeutics Advances mRNA Therapy Pipeline

Cartesian Therapeutics Price Target Maintained With a $41.00/Share by Needham

Buy Rating for Cartesian Therapeutics: Promising Clinical Developments and Strong Financial Position

Analysts Offer Insights on Healthcare Companies: PDS Biotechnology (PDSB) and Cartesian Therapeutics (RNAC)

Cartesian Therapeutics FY 2024 GAAP EPS $(4.49) Beats $(4.98) Estimate, Sales $38.913M Miss $39.777M Estimate

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/RNAC/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"RNAC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RNAC\",,,,,undefined,":{"symbol":"RNAC","market":"US","secType":"STK","nameCN":"Cartesian Therapeutics","latestPrice":11.83,"timestamp":1745611200000,"preClose":12.05,"halted":0,"volume":45578,"hourTrading":{"tag":"盘后","latestPrice":11.83,"preClose":11.83,"latestTime":"16:05 EDT","volume":578,"amount":6837.74,"timestamp":1745611508483},"delay":0,"floatShares":9302905,"shares":25907101,"eps":-4.48613,"marketStatus":"Market Closed","change":-0.22,"latestTime":"04-25 16:00:00 EDT","open":11.87,"high":12.05,"low":11.5074,"amount":537961.4995,"amplitude":0.045029,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-4.48613,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1745827200000},"marketStatusCode":7,"adr":0,"listingDate":1466568000000,"exchange":"NASDAQ","adjPreClose":12.05,"preHourTrading":{"tag":"盘前","latestPrice":11.92,"preClose":12.05,"latestTime":"04:48 EDT","volume":3,"amount":35.440000500000004,"timestamp":1745570908669},"postHourTrading":{"tag":"盘后","latestPrice":11.83,"preClose":11.83,"latestTime":"16:05 EDT","volume":578,"amount":6837.74,"timestamp":1745611508483},"volumeRatio":0.5714737090496524,"impliedVol":1.1151,"impliedVolPercentile":0.4286},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RNAC\",,,,,undefined,":{"symbol":"RNAC","floatShares":9302905,"roa":"-6.00%","roe":"-7029.26%","lyrEps":-4.481379,"volumeRatio":0.5714737090496524,"shares":25907101,"dividePrice":0,"high":12.05,"amplitude":0.045029,"preClose":12.05,"low":11.5074,"week52Low":8.85,"pbRate":"-45.06","psRate":"7.88","week52High":41.87,"institutionHeld":0,"latestPrice":11.83,"eps":-4.48613,"divideRate":0,"volume":45578,"delay":0,"ttmEps":-4.48613,"open":11.87,"prevYearClose":17.91,"prevWeekClose":10.5,"prevMonthClose":13.18,"prevQuarterClose":13.18,"fiveDayClose":10.5,"twentyDayClose":14.36,"sixtyDayClose":19.23},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"RNAC\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2530963963","title":"Cartesian Therapeutics management to meet with BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2530963963","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530963963?lang=en_us&edition=fundamental","pubTime":"2025-04-25 01:06","pubTimestamp":1745514415,"startTime":"0","endTime":"0","summary":"Meeting to be held in Austin and Dallas on May 1 hosted by BTIG. Published first on TheFly – the ultimate source for real-time, market-moving break...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cartesian-therapeutics-management-to-meet-with-btig?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cartesian-therapeutics-management-to-meet-with-btig?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","RNAC"],"gpt_icon":0},{"id":"2526462009","title":"Major Investment Alert: Director Buys Big in Cartesian Therapeutics!","url":"https://stock-news.laohu8.com/highlight/detail?id=2526462009","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526462009?lang=en_us&edition=fundamental","pubTime":"2025-04-12 10:02","pubTimestamp":1744423339,"startTime":"0","endTime":"0","summary":"New insider activity at Cartesian Therapeutics ( ($RNAC) ) has taken place on April 12, 2025. Director Timothy A. Springer has made a significant i...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/major-investment-alert-director-buys-big-in-cartesian-therapeutics?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/major-investment-alert-director-buys-big-in-cartesian-therapeutics?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","RNAC"],"gpt_icon":0},{"id":"2526588372","title":"Buy Rating Affirmed for Cartesian Therapeutics Due to Promising Phase 2b Trial Results and Strong Safety Profile","url":"https://stock-news.laohu8.com/highlight/detail?id=2526588372","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526588372?lang=en_us&edition=fundamental","pubTime":"2025-04-10 14:26","pubTimestamp":1744266376,"startTime":"0","endTime":"0","summary":"Leerink Partners analyst Thomas Smith has reiterated their bullish stance on RNAC stock, giving a Buy rating yesterday. Thomas Smith has given his ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/buy-rating-affirmed-for-cartesian-therapeutics-due-to-promising-phase-2b-trial-results-and-strong-safety-profile?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/buy-rating-affirmed-for-cartesian-therapeutics-due-to-promising-phase-2b-trial-results-and-strong-safety-profile?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RNAC"],"gpt_icon":0},{"id":"2526819368","title":"Cartesian Therapeutics Price Target Maintained With a $40.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2526819368","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526819368?lang=en_us&edition=fundamental","pubTime":"2025-04-09 19:48","pubTimestamp":1744199280,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/RNAC/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 09, 2025 07:48 ET (11:48 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RNAC"],"gpt_icon":0},{"id":"2526980851","title":"Mizuho Securities Sticks to Its Buy Rating for Cartesian Therapeutics (RNAC)","url":"https://stock-news.laohu8.com/highlight/detail?id=2526980851","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526980851?lang=en_us&edition=fundamental","pubTime":"2025-04-09 10:35","pubTimestamp":1744166106,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Uy Ear from Mizuho Securities maintained a Buy rating on Cartesian Therapeutics (RNAC – Research Report), with a pr...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/mizuho-securities-sticks-to-its-buy-rating-for-cartesian-therapeutics-rnac?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/mizuho-securities-sticks-to-its-buy-rating-for-cartesian-therapeutics-rnac?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RNAC","MFG"],"gpt_icon":0},{"id":"2525815476","title":"Cartesian Therapeutics Shares Rise on Positive Phase 2b Trial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2525815476","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525815476?lang=en_us&edition=fundamental","pubTime":"2025-04-08 22:11","pubTimestamp":1744121460,"startTime":"0","endTime":"0","summary":"Shares of Cartesian Therapeutics climbed after the company announced positive results in a phase 2b trial of its lead cell-therapy candidate.The stock was up 8.3% to $15.60 in morning trading Tuesday. Shares are off 39% year to date.The Frederick, Md., clinical-stage maker of therapies for autoimmune diseases said Tuesday that a long-term follow-up assessment of its Descartes-08 treatment showed deep and sustained benefits in participants with generalized myasthenia gravis, or MG. Cartesian said participants at their 12-month follow-up assessment showed an average 4.8-point reduction in the score for MG activities of daily living, or MG-ADL, after a single six-week course of treatment.Cartesian added that the deepest and most-compelling sustained responses were seen in participants without prior exposure to biologic therapies, showing an average 7.1-point reduction in their MG-ADL, and with 57% of these patients maintaining minimum symptom expression at the 12-month follow-up.\"The data","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RNAC","BK4139"],"gpt_icon":0},{"id":"2525898674","title":"BRIEF-Cartesian Therapeutics’ Descartes-08 Observed To Provide Deep And Sustained Benefits Through Month 12 After A Single Course Of Therapy In Phase 2B Myasthenia Gravis Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2525898674","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525898674?lang=en_us&edition=fundamental","pubTime":"2025-04-08 19:04","pubTimestamp":1744110272,"startTime":"0","endTime":"0","summary":"BRIEF-Cartesian Therapeutics’ Descartes-08 Observed To Provide Deep And Sustained Benefits Through Month 12 After A Single Course Of Therapy In Phase 2B Myasthenia Gravis TrialApril 8 (Reuters) - Cart","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250408:nFWN3QM057:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","RNAC"],"gpt_icon":0},{"id":"2525893441","title":"Cartesian Therapeutics’ Descartes-08 Observed to Provide Deep and Sustained Benefits Through Month 12 After a Single Course of Therapy in Phase 2b Myasthenia Gravis Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2525893441","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525893441?lang=en_us&edition=fundamental","pubTime":"2025-04-08 19:00","pubTimestamp":1744110000,"startTime":"0","endTime":"0","summary":"After a single course of therapy, Descartes-08-treated participants were observed to sustain deep responses through long-term follow-up, with an average 4.8-point reduction in MG-ADL at Month 12. Deepest and most compelling sustained responses observed in Descartes-08-treated participants who did not have prior exposure to biologic therapies, with an average 7.1-point reduction in MG-ADL and 57% of patients in this subgroup maintaining minimum symptom expression at Month 12. Safety profile consistent with previously reported data and continues to support outpatient administration. In the Phase 2b double-blind, placebo-controlled, crossover trial, a total of 36 heavily pretreated, highly symptomatic participants with MG were randomized 1:1 to receive either Descartes-08 or placebo administered as six weekly outpatient infusions without preconditioning chemotherapy. As previously announced, the trial met its primary endpoint and demonstrated a safety profile supporting outpatient adminis","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cartesian-therapeutics-descartes-08-observed-110000924.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["RNAC","IE00B19Z4B17.USD","MG","IE00B7SZL793.SGD","BK4123","CRS","IE0031619046.USD","IE00B66KJ199.SGD","BK4023","LU2065731478.USD","MGC","BK4006","BK4139","IE0009354923.USD","DSGX"],"gpt_icon":0},{"id":"2524461325","title":"Cartesian Therapeutics announces employment inducement grants","url":"https://stock-news.laohu8.com/highlight/detail?id=2524461325","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524461325?lang=en_us&edition=fundamental","pubTime":"2025-04-02 19:17","pubTimestamp":1743592623,"startTime":"0","endTime":"0","summary":"Cartesian Therapeutics (RNAC) announced the granting of inducement awards to four new employees. On April 1, 2025, the Company issued to these empl...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cartesian-therapeutics-announces-employment-inducement-grants-3?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cartesian-therapeutics-announces-employment-inducement-grants-3?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","RNAC"],"gpt_icon":0},{"id":"2524693644","title":"Cartesian Therapeutics Announces New Employment Inducement Grants","url":"https://stock-news.laohu8.com/highlight/detail?id=2524693644","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524693644?lang=en_us&edition=fundamental","pubTime":"2025-04-02 19:05","pubTimestamp":1743591900,"startTime":"0","endTime":"0","summary":"FREDERICK, Md., April  02, 2025  (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapies for the treatment of ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/04/02/3054129/0/en/Cartesian-Therapeutics-Announces-New-Employment-Inducement-Grants.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","RNAC"],"gpt_icon":0},{"id":"2520508368","title":"Oppenheimer Reaffirms Their Hold Rating on Cartesian Therapeutics (RNAC)","url":"https://stock-news.laohu8.com/highlight/detail?id=2520508368","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520508368?lang=en_us&edition=fundamental","pubTime":"2025-03-18 00:55","pubTimestamp":1742230505,"startTime":"0","endTime":"0","summary":"In a report released today, Matthew Biegler from Oppenheimer reiterated a Hold rating on Cartesian Therapeutics (RNAC – Research Report). The compa...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/oppenheimer-reaffirms-their-hold-rating-on-cartesian-therapeutics-rnac?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/oppenheimer-reaffirms-their-hold-rating-on-cartesian-therapeutics-rnac?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["OPY","RNAC"],"gpt_icon":0},{"id":"2520561990","title":"Buy Rating for Cartesian Therapeutics: Promising Advancements in Biopharmaceuticals and Strategic Clinical Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2520561990","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520561990?lang=en_us&edition=fundamental","pubTime":"2025-03-17 14:16","pubTimestamp":1742192174,"startTime":"0","endTime":"0","summary":"In a report released on March 14, Thomas Smith from Leerink Partners maintained a Buy rating on Cartesian Therapeutics (RNAC – Research Report), wi...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/buy-rating-for-cartesian-therapeutics-promising-advancements-in-biopharmaceuticals-and-strategic-clinical-progress?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/buy-rating-for-cartesian-therapeutics-promising-advancements-in-biopharmaceuticals-and-strategic-clinical-progress?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PRGS","RNAC"],"gpt_icon":0},{"id":"2519387387","title":"Amgen data ‘muddies’ outlook for Cartesian, says Oppenheimer","url":"https://stock-news.laohu8.com/highlight/detail?id=2519387387","media":"TipRanks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519387387?lang=en_us&edition=fundamental","pubTime":"2025-03-15 00:15","pubTimestamp":1741968914,"startTime":"0","endTime":"0","summary":"Oppenheimer reiterates a Perform rating on Cartesian Therapeutics  without a price target following the company’s Q4 report. The company’s Phase 3 trial in myasthenia gravis remains on track to start by mid-year, the analyst tells investors in a research note. The firm thinks the trial has a “decent chance at working,” but does not currently view Descartes-08 as a commercially viable therapy. Just today, Amgen  announced updated Uplizna results showing a deepening of responses six months after a single repeat infusion, Opco points out. It believes extrapolating from Cartesian’s Phase 2, Descartes-08 would likely need six additional infusions to show a similar benefit. The Uplizna study “muddies” commercial outlook for Cartesian, the firm contends.Discover stocks' market position with detailed  competitor analyses.Read More on RNAC:Questions or Comments about the article?Cartesian Therapeutics reports FY24 EPS  vs.  last year","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/amgen-data-muddies-outlook-cartesian-161514365.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/amgen-data-muddies-outlook-cartesian-161514365.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4566","AMGN","BK4534","BK4139","IE00BFTCPJ56.SGD","LU0109394709.USD","RNAC","IE00BJT1NW94.SGD","IE00BJJMRZ35.SGD","LU1057294990.SGD","BK4127","LU1061106388.HKD","LU0868494617.USD","LU0058720904.USD","BK4585","LU2112291526.USD","LU0889565916.HKD","IE00B4R5TH58.HKD","LU2242652126.USD","OPY","IE0002141913.USD","LU1571399168.USD","BK4599","IE00B2B36J28.USD","LU0122379950.USD","LU0289739699.SGD","BK4588","LU0320765992.SGD","IE0009355771.USD","BK4533","SG9999001440.SGD","LU1023059063.AUD","LU1983299246.USD","BK4581","LU2242646821.SGD"],"gpt_icon":0},{"id":"2519879724","title":"Cartesian Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag","url":"https://stock-news.laohu8.com/highlight/detail?id=2519879724","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519879724?lang=en_us&edition=fundamental","pubTime":"2025-03-14 18:13","pubTimestamp":1741947221,"startTime":"0","endTime":"0","summary":"NasdaqGM:RNAC Earnings and Revenue History March 14th 2025. All figures shown in the chart above are for the trailing 12 month  period. Revenue missed analyst estimates by 2.1%. Earnings per share  exceeded analyst estimates by 24%.Looking ahead, revenue is forecast to grow 37% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Biotechs industry in the US.The company's shares are down 6.9% from a week ago.We should say that we've discovered 4 warning signs for Cartesian Therapeutics (3 are a bit concerning!) that you should be aware of before investing here.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cartesian-therapeutics-full-2024-earnings-101341362.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["RNAC"],"gpt_icon":0},{"id":"2519846354","title":"Cartesian Therapeutics Faces Financial Risk from Goodwill and Intangible Asset Impairments Post-Merger","url":"https://stock-news.laohu8.com/highlight/detail?id=2519846354","media":"TIPRANKS","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519846354?lang=en_us&edition=fundamental","pubTime":"2025-03-14 14:00","pubTimestamp":1741932035,"startTime":"0","endTime":"0","summary":"Cartesian Therapeutics, Inc. (RNAC) has disclosed a new risk, in the Accounting & Financial Operations category. Cartesian Therapeutics, Inc. faces...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/cartesian-therapeutics-faces-financial-risk-from-goodwill-and-intangible-asset-impairments-post-merger?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/cartesian-therapeutics-faces-financial-risk-from-goodwill-and-intangible-asset-impairments-post-merger?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4212","BK4139","POST","RNAC"],"gpt_icon":0},{"id":"2519817425","title":"Cartesian Therapeutics Advances mRNA Therapy Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2519817425","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519817425?lang=en_us&edition=fundamental","pubTime":"2025-03-14 12:14","pubTimestamp":1741925695,"startTime":"0","endTime":"0","summary":"Cartesian Therapeutics, Inc. ( ($RNAC) ) has released its Q4 earnings. Here is a breakdown of the information Cartesian Therapeutics, Inc. presente...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/cartesian-therapeutics-advances-mrna-therapy-pipeline?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/cartesian-therapeutics-advances-mrna-therapy-pipeline?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","RNAC"],"gpt_icon":0},{"id":"2519850295","title":"Cartesian Therapeutics Price Target Maintained With a $41.00/Share by Needham","url":"https://stock-news.laohu8.com/highlight/detail?id=2519850295","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519850295?lang=en_us&edition=fundamental","pubTime":"2025-03-14 02:02","pubTimestamp":1741888920,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/RNAC/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 13, 2025 14:02 ET (18:02 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RNAC"],"gpt_icon":0},{"id":"2519850058","title":"Buy Rating for Cartesian Therapeutics: Promising Clinical Developments and Strong Financial Position","url":"https://stock-news.laohu8.com/highlight/detail?id=2519850058","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519850058?lang=en_us&edition=fundamental","pubTime":"2025-03-14 01:55","pubTimestamp":1741888516,"startTime":"0","endTime":"0","summary":"Analyst Gil Blum from Needham maintained a Buy rating on Cartesian Therapeutics (RNAC – Research Report) and keeping the price target at $41.00. Gi...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/buy-rating-for-cartesian-therapeutics-promising-clinical-developments-and-strong-financial-position?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/buy-rating-for-cartesian-therapeutics-promising-clinical-developments-and-strong-financial-position?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RNAC"],"gpt_icon":0},{"id":"2519285441","title":"Analysts Offer Insights on Healthcare Companies: PDS Biotechnology (PDSB) and Cartesian Therapeutics (RNAC)","url":"https://stock-news.laohu8.com/highlight/detail?id=2519285441","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519285441?lang=en_us&edition=fundamental","pubTime":"2025-03-14 00:30","pubTimestamp":1741883409,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on PDS Biotechnology (PDSB – Research Report) and Cartesian Therapeu...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-pds-biotechnology-pdsb-and-cartesian-therapeutics-rnac?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-pds-biotechnology-pdsb-and-cartesian-therapeutics-rnac?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RNAC","PDS","BK4137","PDSB","BK4092","BK4139","HCSG"],"gpt_icon":0},{"id":"2519960880","title":"Cartesian Therapeutics FY 2024 GAAP EPS $(4.49) Beats $(4.98) Estimate, Sales $38.913M Miss $39.777M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2519960880","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519960880?lang=en_us&edition=fundamental","pubTime":"2025-03-13 19:16","pubTimestamp":1741864612,"startTime":"0","endTime":"0","summary":"Cartesian Therapeutics FY 2024 GAAP EPS $(4.49) Beats $(4.98) Estimate, Sales $38.913M Miss $39.777M Estimate","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/03/44298634/cartesian-therapeutics-fy-2024-gaap-eps-4-49-beats-4-98-estimate-sales-38-913m-miss-39-777m-estimat","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Cartesian Therapeutics FY 2024 GAAP EPS $(4.49) Beats $(4.98) Estimate, Sales $38.913M Miss $39.777M Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RNAC"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":1,"totalSize":72,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/RNAC\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-03-13","symbol":"RNAC","fiscalQuarterEnding":"2024/12","expectedEps":-0.78,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1741838400000,"reportTimeType":"pre","actualEps":-2.4},{"market":"US","date":"2024-11-07","symbol":"RNAC","fiscalQuarterEnding":"2024/09","expectedEps":-0.78,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1730955600000,"reportTimeType":"pre","actualEps":-0.69},{"market":"US","date":"2024-08-08","symbol":"RNAC","fiscalQuarterEnding":"2024/06","expectedEps":-0.81,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1723089600000,"reportTimeType":"pre","actualEps":0.54},{"market":"US","date":"2024-05-08","symbol":"RNAC","fiscalQuarterEnding":"2024/03","expectedEps":-0.81,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1715140800000,"reportTimeType":"pre","actualEps":-1.97},{"market":"US","date":"2024-04-05","symbol":"RNAC","defaultRemindTime":1712323800000,"type":"split","dateTimestamp":1712289600000,"forFactor":30,"toFactor":1,"ratio":30}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"RNAC\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"RNAC\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.25,"buy":0.5,"hold":0.25,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5,"analysts":8,"updateTime":1734667200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/RNAC\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"RNAC","date":"2025-04-25","current":-4.03209,"percent":0.135417,"low":-14.109752,"twenty":-2.511189,"median":-1.940728,"eighty":-1.376163,"high":-0.322359,"avg":-2.801743,"sd":3.010294,"marketCap":312180567},"quantilePoints":[{"date":"2024-02-09","current":-12.195228,"twenty":-12.293822,"median":-12.139657,"eighty":-11.530164,"marketCap":110159496},{"date":"2024-02-16","current":-13.543282,"twenty":-12.82193,"median":-12.371802,"eighty":-12.018117,"marketCap":122336468},{"date":"2024-02-23","current":-12.9069,"twenty":-13.170416,"median":-12.72226,"eighty":-12.169773,"marketCap":116588031},{"date":"2024-03-01","current":-13.113052,"twenty":-13.187625,"median":-12.9069,"eighty":-12.193077,"marketCap":118450201},{"date":"2024-03-08","current":-0.474472,"twenty":-13.096919,"median":-12.72226,"eighty":-12.104521,"marketCap":104246325},{"date":"2024-03-15","current":-0.394571,"twenty":-13.085087,"median":-12.369113,"eighty":-0.499332,"marketCap":86691095},{"date":"2024-03-22","current":-0.518772,"twenty":-13.077916,"median":-12.18985,"eighty":-0.473381,"marketCap":113979437},{"date":"2024-03-28","current":-0.486782,"twenty":-13.018401,"median":-12.095738,"eighty":-0.472836,"marketCap":106950867},{"date":"2024-04-05","current":-0.371573,"twenty":-12.924109,"median":-11.522994,"eighty":-0.462369,"marketCap":81638284},{"date":"2024-04-12","current":-1.459867,"twenty":-12.9069,"median":-1.226402,"eighty":-0.444134,"marketCap":320747357},{"date":"2024-04-19","current":-1.398365,"twenty":-12.846668,"median":-1.459867,"eighty":-0.462369,"marketCap":307234719},{"date":"2024-04-26","current":-1.691309,"twenty":-12.729072,"median":-1.487381,"eighty":-0.467868,"marketCap":371597548},{"date":"2024-05-03","current":-1.978779,"twenty":-12.63227,"median":-1.536745,"eighty":-0.471303,"marketCap":434757574},{"date":"2024-05-10","current":-1.526348,"twenty":-12.47667,"median":-1.594687,"eighty":-0.472836,"marketCap":389021718},{"date":"2024-05-17","current":-1.839158,"twenty":-12.299559,"median":-1.62026,"eighty":-0.47633,"marketCap":468748036},{"date":"2024-05-24","current":-1.777713,"twenty":-12.193077,"median":-1.671483,"eighty":-0.482182,"marketCap":453087509},{"date":"2024-05-31","current":-2.195259,"twenty":-12.18985,"median":-1.697348,"eighty":-0.489671,"marketCap":559507906},{"date":"2024-06-07","current":-2.422885,"twenty":-12.179811,"median":-1.717665,"eighty":-0.504164,"marketCap":617523039},{"date":"2024-06-14","current":-2.045138,"twenty":-12.139657,"median":-1.777713,"eighty":-0.515905,"marketCap":521246392},{"date":"2024-06-21","current":-1.598266,"twenty":-12.069386,"median":-1.728138,"eighty":-0.518199,"marketCap":407351653},{"date":"2024-06-28","current":-1.991374,"twenty":-11.947846,"median":-1.777713,"eighty":-0.520305,"marketCap":507543431},{"date":"2024-07-05","current":-1.23169,"twenty":-11.531957,"median":-1.728138,"eighty":-0.526438,"marketCap":313922113},{"date":"2024-07-12","current":-1.241477,"twenty":-11.522994,"median":-1.709478,"eighty":-0.530124,"marketCap":316416386},{"date":"2024-07-15","current":-1.240079,"twenty":-9.729226,"median":-1.703386,"eighty":-0.53751,"marketCap":316060062},{"date":"2024-08-02","current":-1.081399,"twenty":-7.935458,"median":-1.699966,"eighty":-0.544895,"marketCap":275617201},{"date":"2024-08-09","current":-1.198323,"twenty":-2.548847,"median":-1.676743,"eighty":-0.772791,"marketCap":275192581},{"date":"2024-08-16","current":-1.345437,"twenty":-2.529995,"median":-1.625846,"eighty":-1.101689,"marketCap":308976908},{"date":"2024-08-23","current":-1.244878,"twenty":-2.507232,"median":-1.598266,"eighty":-1.148418,"marketCap":285883824},{"date":"2024-08-30","current":-1.388267,"twenty":-2.46827,"median":-1.531547,"eighty":-1.172903,"marketCap":318812851},{"date":"2024-09-06","current":-1.307262,"twenty":-2.424002,"median":-1.519153,"eighty":-1.173531,"marketCap":300210089},{"date":"2024-09-13","current":-1.496275,"twenty":-2.390626,"median":-1.497092,"eighty":-1.177113,"marketCap":343616533},{"date":"2024-09-20","current":-1.540036,"twenty":-2.248325,"median":-1.497406,"eighty":-1.182548,"marketCap":353666301},{"date":"2024-09-27","current":-1.616387,"twenty":-2.173184,"median":-1.49772,"eighty":-1.183457,"marketCap":371199939},{"date":"2024-10-04","current":-2.374287,"twenty":-2.173184,"median":-1.519153,"eighty":-1.187433,"marketCap":545250240},{"date":"2024-10-11","current":-2.176603,"twenty":-2.352646,"median":-1.530726,"eighty":-1.193387,"marketCap":499852543},{"date":"2024-10-18","current":-2.257757,"twenty":-2.310612,"median":-1.544226,"eighty":-1.200277,"marketCap":518489492},{"date":"2024-10-25","current":-2.299664,"twenty":-2.339564,"median":-1.569114,"eighty":-1.208188,"marketCap":528113202},{"date":"2024-10-31","current":-2.199769,"twenty":-2.325678,"median":-1.616387,"eighty":-1.208566,"marketCap":505172538},{"date":"2024-11-08","current":-2.028231,"twenty":-2.320475,"median":-1.625846,"eighty":-1.217877,"marketCap":496569789},{"date":"2024-11-15","current":-1.766791,"twenty":-2.31186,"median":-1.676743,"eighty":-1.221601,"marketCap":432561563},{"date":"2024-11-22","current":-1.725268,"twenty":-2.307988,"median":-1.693927,"eighty":-1.221601,"marketCap":422395604},{"date":"2024-11-29","current":-1.954681,"twenty":-2.306323,"median":-1.709478,"eighty":-1.229672,"marketCap":478562529},{"date":"2024-12-06","current":-2.388593,"twenty":-2.306323,"median":-1.725268,"eighty":-1.23169,"marketCap":584796802},{"date":"2024-12-13","current":-2.088591,"twenty":-2.321516,"median":-1.757967,"eighty":-1.238401,"marketCap":511347747},{"date":"2024-12-20","current":-2.024787,"twenty":-2.313583,"median":-1.76875,"eighty":-1.241197,"marketCap":495726646},{"date":"2024-12-27","current":-2.088883,"twenty":-2.309537,"median":-1.777713,"eighty":-1.243092,"marketCap":511419083},{"date":"2025-01-03","current":-1.778913,"twenty":-2.307156,"median":-1.777862,"eighty":-1.244452,"marketCap":435529430},{"date":"2025-01-10","current":-1.777862,"twenty":-2.305849,"median":-1.777862,"eighty":-1.244878,"marketCap":435272177},{"date":"2025-01-17","current":-1.989062,"twenty":-2.304427,"median":-1.779554,"eighty":-1.246554,"marketCap":486980042},{"date":"2025-01-24","current":-2.040548,"twenty":-2.299664,"median":-1.784789,"eighty":-1.253258,"marketCap":499585442},{"date":"2025-01-31","current":-2.036345,"twenty":-2.283748,"median":-1.80308,"eighty":-1.272811,"marketCap":498556430},{"date":"2025-02-07","current":-1.976453,"twenty":-2.276485,"median":-1.8278,"eighty":-1.28026,"marketCap":483893005},{"date":"2025-02-14","current":-1.999569,"twenty":-2.273364,"median":-1.845442,"eighty":-1.299813,"marketCap":489552573},{"date":"2025-02-21","current":-2.060513,"twenty":-2.263946,"median":-1.859179,"eighty":-1.303538,"marketCap":504473250},{"date":"2025-02-28","current":-1.892393,"twenty":-2.258524,"median":-1.87682,"eighty":-1.306703,"marketCap":463312761},{"date":"2025-03-07","current":-1.875581,"twenty":-2.211367,"median":-1.875581,"eighty":-1.307262,"marketCap":459196712},{"date":"2025-03-14","current":-5.557927,"twenty":-2.211367,"median":-1.881886,"eighty":-1.317995,"marketCap":430316947},{"date":"2025-03-21","current":-5.33039,"twenty":-2.277938,"median":-1.88594,"eighty":-1.323353,"marketCap":412700118},{"date":"2025-03-28","current":-4.805047,"twenty":-2.306323,"median":-1.893969,"eighty":-1.325512,"marketCap":372025970},{"date":"2025-04-04","current":-4.129128,"twenty":-2.32984,"median":-1.905491,"eighty":-1.337057,"marketCap":319693626},{"date":"2025-04-11","current":-3.466594,"twenty":-2.375387,"median":-1.926854,"eighty":-1.34432,"marketCap":268397566},{"date":"2025-04-17","current":-3.536863,"twenty":-2.423443,"median":-1.931271,"eighty":-1.357169,"marketCap":273838057},{"date":"2025-04-25","current":-4.03209,"twenty":-2.511189,"median":-1.940728,"eighty":-1.376163,"marketCap":312180567}],"updateTime":1745740139914}}}